Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated Fundamental Analysis
Corcept Therapeutics Incorporated (CORT) shows moderate financial fundamentals with a PE ratio of 33.72, profit margin of 13.01%, and ROE of 15.25%. The company generates $0.8B in annual revenue with strong year-over-year growth of 39.94%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 77.0/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze CORT's fundamental strength across five key dimensions:
Efficiency Score
ExcellentCORT demonstrates superior asset utilization.
Valuation Score
ModerateCORT shows balanced valuation metrics.
Growth Score
ExcellentCORT delivers strong and consistent growth momentum.
Financial Health Score
ExcellentCORT maintains a strong and stable balance sheet.
Profitability Score
ModerateCORT maintains healthy but balanced margins.
Key Financial Metrics
Is CORT Expensive or Cheap?
P/E Ratio
CORT trades at 33.72 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, CORT's PEG of -6.74 indicates potential undervaluation.
Price to Book
The market values Corcept Therapeutics Incorporated at 5.16 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 61.90 times EBITDA. This signals the market has high growth expectations.
How Well Does CORT Make Money?
Net Profit Margin
For every $100 in sales, Corcept Therapeutics Incorporated keeps $13.01 as profit after all expenses.
Operating Margin
Core operations generate 5.88 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.25 in profit for every $100 of shareholder equity.
ROA
Corcept Therapeutics Incorporated generates $11.84 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Corcept Therapeutics Incorporated produces operating cash flow of $145.43M, showing steady but balanced cash generation.
Free Cash Flow
Corcept Therapeutics Incorporated generates strong free cash flow of $145.21M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.37 in free cash annually.
FCF Yield
CORT converts 4.16% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
33.72
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-6.74
vs 25 benchmark
P/B Ratio
Price to book value ratio
5.16
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.49
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.009
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.92
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.15
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
0.07
vs 25 benchmark
How CORT Stacks Against Its Sector Peers
| Metric | CORT Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 33.72 | 28.25 | Worse (Expensive) |
| ROE | 15.25% | 780.00% | Weak |
| Net Margin | 13.01% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.01 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 2.92 | 4.66 | Strong Liquidity |
| ROA | 11.84% | -14687.00% (disorted) | Strong |
CORT outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Corcept Therapeutics Incorporated's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
143.97%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
64.34%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
61.18%
Industry Style: Defensive, Growth, Innovation
High Growth